LOXL2 and carcinoma of esophagus: The recently described constitutive L2ΔE13-KI splice variant model has been crucial in identifying the novel deacetylase activity of Loxl2 and the L2ΔE13 variant, which promotes metabolic reprogramming and tumour progression in oesophageal cancer [16].